Therapeutic Expertise
For expertise related specifically to Melanoma, please click here.
|
The 4th International Symposium on Cancer Metastasis and the Lymphovasular System: Basis for Rationale Therapy - This 2.5-day multi-grantor CME-certified conference in New York City, chaired by Stanley P. L. Leong, MD, FACS, and featuring dozens of world-renowned cancer experts, was designed to help participants improve their expertise in detecting and managing cancer metastasis from its inception in the tumor microenvironment through its progression to metastatic potential at distant sites by way of the lymphovascular system, oftentimes in an orderly fashion via the SLN gateway. In collaboration with the Sentinel Node Oncology Foundation/Sentinel Lymph Node Working Group and Sutter Pacific Medical Foundation, the satellite symposium was also sponsored by the National Cancer Institute, The Arizona Cancer Center, AIM at Melanoma, and The Melanoma Research Foundation. The target audience included US and international physicians and researchers involved in all oncology disciplines.
|
|
Advances in Diagnosis and Treatment of Non-small Cell Lung Cancer (NSCLC) - This live CME Symposium chaired by Nasser K. Altorki, MD, was designed to synthesize the burgeoning NSCLC expert knowledge base for the benefit of healthcare professionals responsible for managing NSCLC patients, with the ultimate goal of facilitating individualized care and improving survival rates for a broader selection of NSCLC patients. Target audience: thoracic surgeons, surgical oncologists, medical oncologists, radiation oncologists, pulmonologists, GP/IM physicians, and respiratory therapists.
|
|
|
Promising New Therapies in Kidney Cancer: Update and Panel Discussion - Presented as a satellite symposium at The Oncology World Congress, this live CME activity, jointly sponsored with the Elsevier Office of Continuing Medical Education, provided an overview of the latest data on key promising agents in kidney cancer as well as a panel discussion in which experts put these promising therapies into context. Target audience: community oncologists, pediatric oncologists, radiation oncologists, surgical oncologists, and urologists.
|
)
)